Innovation Activities and Developments

Earlier this year, MSK announced the formation of MSK Ventures, a dedicated venture capital fund which will enable MSK to systematically invest in and help develop, scale, and, in some instances, translate new discoveries and services while diversifying long-term revenue streams. Whitney Snider, MD, joined MSK as Inaugural Managing Partner, after most recently serving as Principle and Vice President of Life Sciences at Alexandria Venture Investments.

In a pivotal move to revolutionize the clinical research landscape, the MSK Clinical Research Innovation Consortium (CRIC) held its inaugural kick-off meeting in November 2025. Spearheaded by founding member MSK, the meeting welcomed new CRIC members Moffitt Cancer Center, Huntsman Cancer Institute, and the Tisch Cancer Center of Mount Sinai Health System.

The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program will facilitate tailored mentorship with MSK faculty, while providing access to MSK’s drug development expertise, resources, and a pathway for future collaboration in the MSK Therapeutics Accelerator.

For clinical research stakeholders, implementing and scaling electronic source date (eSource) is a priority. With participation from MSK, a number of Society of Clinical Data Management (SCDM) working groups have collaborated on a paper outlining consensus recommendations on eSource best practices.

On Tuesday, December 2, MSK hosted "Demo Day 2025," a strong follow-up to the institution’s November 2025 “Innovation with Lasting Impact Summit” on entrepreneurship and innovation.

MSK is a founding member of the Cancer AI Alliance (CAIA), an exciting collaborative research initiative designed to accelerate development and deployment of AI models to improve cancer care. This unique alliance unites four leading NCI-designated cancer centers — MSK, Dana-Farber Cancer Institute, Fred Hutch Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins — with technology powerhouses that include Ai2, Amazon, Deloitte, Google, Microsoft, Nvidia, and Slalom.

On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.

Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials.

May is Clinical Trials Awareness Month, culminating on May 20 with International Clinical Trials Day. For institutions like ours, this is an opportunity to commemorate the importance of clinical research and the valued contributions of clinical research professionals around the world.

For the first time, MSK has been named one of Fast Company’s Best Workplaces for Innovators, ranking No. 9 out of 100 on its 2025 list of awardees.